Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

NCT01461837 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: CD34 selected T-cell depleted allogeneic SCT

Sponsor

New York Medical College

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]